Newron starts late-stage ralfinamide trial in back pain
This article was originally published in Scrip
Executive Summary
Newron Pharmaceuticalshas received approval to begin its first Phase IIb/III trial of its neuropathic pain candidate, ralfinamide (NW-129), in the product’s lead indication, moderate neuropathic lower back pain. There is no drug approved specifically for NLBP.